Results 151 to 160 of about 130,663 (190)

MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection. [PDF]

Front Immunol
Koch-Heier J, Vogel AB, Füll Y, Ebensperger M, Schönsiegel A, Zinser RS, Planz O.   +6 more
europepmc   +1 more source

Case report: MEK inhibitor as treatment for multi-lineage mosaic KRAS G12D-associated epidermal nevus syndrome in a pediatric patient. [PDF]

Front Neurol
Dionysiou M, Makri SC, Ahlawat S, Guryildirim M, Barañano KW, Groves ML, Argani P, Pratilas CA.   +7 more
europepmc   +1 more source

Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia. [PDF]

Clin Cancer Res
Modak RV, de Oliveira Rebola KG, McClatchy J, Mohammadhosseini M, Damnernsawad A, Kurtz SE, Eide CA, Wu G, Laderas T, Nechiporuk T, Gritsenko MA, Hansen JR, Hutchinson C, Gosline SJC, Piehowski P, Bottomly D, Short N, Rodland K, McWeeney SK, Tyner JW, Agarwal A.   +20 more
europepmc   +1 more source

Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib. [PDF]

Cancers (Basel)
Kim J, Lee TS, Lee MH, Cho IR, Ryu JK, Kim YT, Lee SH, Paik WH.   +7 more
europepmc   +1 more source

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination. [PDF]

Gynecol Oncol Rep
Singh M, Cornwell S, Shaddaie A, Wachsmuth L, Ragupathi A, Salichos L, Nissel-Horowitz S, Roy R, Plummer M, Zhang D, Mehrotra B.   +10 more
europepmc   +1 more source

Drug-resistant BRAF V600E-mutant recurrent pleomorphic xanthoastrocytoma, CNS WHO Grade 3 successfully resolved with incidental discontinuation of combined BRAF and MEK inhibitor therapy. [PDF]

Surg Neurol Int
Inoue H, Kuroda JI, Fujioka Y, Hata N, Mizoguchi M, Yoshii D, Sueyoshi H, Takeshima Y, Fujimoto K, Shinojima N, Sunami K, Mikami Y, Nakamura H, Mukasa A.   +13 more
europepmc   +1 more source